Fig. 1.

Chemical screening identifies small molecules that protect cardiomyocytes (CMs) against H₂O₂-induced oxidative injury. A Schematic of high-throughput screening of small molecules that suppress H₂O₂-induced injury of NRVMs by LDH assay. B Flowchart showing two-round chemical screening for small molecules that decrease H₂O₂-induced CM death. C The first-round chemical screening identifies 30 small molecules from 3,143 FDA-approved compounds based on LDH assays, where NRVMs are exposed to H₂O₂ (200 μM) in the presence of 2 mM compounds for 24 h. n = 3 per group. D The second-round screening confirms 5 candidate small molecules, each of which has a dose-dependent effect on LDH release in the presence of 1, 2, 5, or 10 μM compounds for 24 h. n = 4 per group. E The chemical structures of 5 candidate small molecules. 1-C7, Veliparib (dihydrochloride); 1-G3, Olmutinib; 2-F13, Oxeladin (citrate); 2-F14, Pitavastatin (Calcium); 2-F16, Disulfiram (DSF). *p < 0.1, **p < 0.01, ***p < 0.001; ns, no significant difference. One-way ANOVA with Dunnett’s test (C, D). Data are the mean ± s.e.m. (C, D)